GLP Watchdog

Does UnitedHealthcare Pay for GLP-1 Medications? (2026)

Whether UnitedHealthcare covers a GLP-1 depends on your specific plan; prior authorization is required, and members who are approved typically pay $30-$100 a month.

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

Where UnitedHealthcare stands[1]
Depends on the Plan
49,800,000 members · Prior authorization needed[1]
Depends on the Plan

If your question is only about Wegovy and Zepbound, read does UnitedHealthcare cover Zepbound and Wegovy, which covers the employer opt-in and the sleep apnea and heart-risk programs that work on plans excluding weight loss.

Where Each Medication Stands[5]

How UHC handles each GLP-1, and the usual copay when one is covered. Copay in USD per month.
MedicationWhat UHC does
Wegovy (semaglutide)UnitedHealthcare's own drug-list notices say weight-loss medications are excluded under most of its benefit plans, so the first question is whether the employer bought weight-loss coverage. Where it did, Wegovy injection and Wegovy HD go through UHC's weight-loss prior authorization (2026 P 1114-23, effective 10/1/2026), which UHC describes as an optional program for clients that elect it. Patients need a BMI of 30 or more (27 or more when a weight-related condition is present), and the drug has to be paired with lifestyle changes; the injection is open from age 12. The first approval is 5 months, a one-time extra 6 months is allowed for anyone still titrating, and renewals run 12 months on >=5% loss from baseline weight. Wegovy tablets are typically excluded, and the January 1, 2027 Advantage 4-Tier PDL notice lists the tablet among excluded drugs. On plans that exclude weight loss, a separate non-formulary program (2026 P 1445-4, effective 5/1/2026) can still cover Wegovy for cardiovascular risk reduction - age 45 or older, BMI >=27, an earlier heart attack, stroke or leg-artery disease with symptoms, and no diabetes - and the injection for MASH at fibrosis stage F2-F3, 12 months at a time.
Ozempic (semaglutide)Paid for type 2 diabetes once a prior authorization is approved under UHC's GLP-1 diabetes program (2026 P 1332-8, effective 7/1/2026): medical records have to confirm the diagnosis, by A1C >=6.5% or a qualifying glucose result, and approval runs 12 months. UHC adds that weight-loss use is typically a benefit exclusion.
Zepbound (tirzepatide)Zepbound for weight loss is covered only on plans whose employer elected weight-loss coverage, through the same optional UHC prior authorization (2026 P 1114-23, effective 10/1/2026): the same BMI test (30, or 27 when a weight-related condition is present) paired with lifestyle changes, for patients over 16. The first approval is 6 months, with a one-time extra 6 months for anyone still titrating, then 12-month renewals on >=5% weight loss. Weight-loss medications are excluded under most UHC plans. On those plans, a separate non-formulary program (2026 P 1475-3, effective 9/1/2026) can still cover Zepbound for obstructive sleep apnea: adults with BMI >=30, a sleep study showing AHI >15, no diabetes, and OSA symptoms despite PAP use (or a reason PAP is not an option). It is approved 6 months at a time at first; renewal on PAP requires >=10% loss of baseline body weight.
Mounjaro (tirzepatide)Covered for type 2 diabetes under the same UHC program as Ozempic (2026 P 1332-8, effective 7/1/2026): records confirming the diagnosis are required, and approval runs 12 months. The 2026 criteria do not list a metformin step; the plan's own drug list may still add one.
Copay when it is covered$30-$100 / month

What a GLP-1 costs a UnitedHealthcare member

At UnitedHealthcare's typical copay of $30-$100 a month, a covered year of a GLP-1 costs $360 to $1,200. That is $2,988 to $3,828 less than a year of Wegovy bought for cash from NovoCare ($4,188), and Zepbound's LillyDirect price of $299 to $449 a month is further above it still.

The cheapest compounded option, WellMedRx at $49/mo ($588 a year), lands inside the UHC range, and 44 sellers charge no more than the $100 top of it, so for a member facing that copay a denial costs less than it sounds.

When UHC covers the drug, a manufacturer savings card can bring a Wegovy or Zepbound fill down to $25, with each maker paying at most $100 a month.

Employers whose plans run through UHC

Your employer decides much of this. Among the employers in our coverage checker, 3 use UHC to run medical or pharmacy benefits: FedEx, JPMorgan Chase and Paychex. FedEx's Wegovy position, for example: Covered for clinically eligible members via Calibrate program; Calibrate enrollment is required for coverage of GLP-1 weight-loss drugs (copay varies by FedEx plan).

After a Denial from UnitedHealthcare

A UHC denial leaves two routes: an appeal, and paying cash. With a prescription, a brand-name GLP-1 is generally an eligible HSA or FSA medical expense[3]. Compounded semaglutide and tirzepatide from licensed 503A pharmacies[4] cost far less than the brand; the cheapest sellers are listed below.

If a large employer self-funds your UHC plan, ERISA rather than state insurance law applies and the employer decides whether anti-obesity drugs are covered[2]; the Summary Plan Description says which.

Where to go if UnitedHealthcare says no

Sellers that say they work with UHC

Sellers that mention UHC
#SellerCash priceVisit
1EvernowPrice not publishedReview

The 8 cheapest cash-pay compounded GLP-1s

Cheapest cash-pay compounded GLP-1 sellers
#SellerMonthly priceVisit
1WellMedRx
Compounded semaglutide
$49/moVisit
2Collective
Compounded semaglutide
$59/moVisit
3RenewlyRX
Compounded semaglutide
$68/moReview
4Lean Meds
Compounded semaglutide
$79/moReview
5Tryozi
Compounded semaglutide
$79/moReview
6Embody
Compounded semaglutide
$79/moVisit
7NextMeds
Compounded semaglutide
$79/moReview
8CoreAge Rx
Compounded semaglutide
$79/moVisit

Every seller and price, side by side: compare all sellers.

Our picks

Starting price per provider. Prices in USD per month; checked November 2026.
#ProviderScore
1EmbodyVisit
2CollectiveVisit
3AgelessRxVisit
4EdenVisit
5YourEraVisit

Frequently Asked Questions

UnitedHealthcare's own drug-list notices say weight-loss medications are excluded under most of its benefit plans, so the first question is whether the employer bought weight-loss coverage. Where it did, Wegovy injection and Wegovy HD go through UHC's weight-loss prior authorization (2026 P 1114-23, effective 10/1/2026), which UHC describes as an optional program for clients that elect it. Patients need a BMI of 30 or more (27 or more when a weight-related condition is present), and the drug has to be paired with lifestyle changes; the injection is open from age 12. The first approval is 5 months, a one-time extra 6 months is allowed for anyone still titrating, and renewals run 12 months on >=5% loss from baseline weight. Wegovy tablets are typically excluded, and the January 1, 2027 Advantage 4-Tier PDL notice lists the tablet among excluded drugs. On plans that exclude weight loss, a separate non-formulary program (2026 P 1445-4, effective 5/1/2026) can still cover Wegovy for cardiovascular risk reduction - age 45 or older, BMI >=27, an earlier heart attack, stroke or leg-artery disease with symptoms, and no diabetes - and the injection for MASH at fibrosis stage F2-F3, 12 months at a time.
Paid for type 2 diabetes once a prior authorization is approved under UHC's GLP-1 diabetes program (2026 P 1332-8, effective 7/1/2026): medical records have to confirm the diagnosis, by A1C >=6.5% or a qualifying glucose result, and approval runs 12 months. UHC adds that weight-loss use is typically a benefit exclusion.
Zepbound for weight loss is covered only on plans whose employer elected weight-loss coverage, through the same optional UHC prior authorization (2026 P 1114-23, effective 10/1/2026): the same BMI test (30, or 27 when a weight-related condition is present) paired with lifestyle changes, for patients over 16. The first approval is 6 months, with a one-time extra 6 months for anyone still titrating, then 12-month renewals on >=5% weight loss. Weight-loss medications are excluded under most UHC plans. On those plans, a separate non-formulary program (2026 P 1475-3, effective 9/1/2026) can still cover Zepbound for obstructive sleep apnea: adults with BMI >=30, a sleep study showing AHI >15, no diabetes, and OSA symptoms despite PAP use (or a reason PAP is not an option). It is approved 6 months at a time at first; renewal on PAP requires >=10% loss of baseline body weight.
Covered for type 2 diabetes under the same UHC program as Ozempic (2026 P 1332-8, effective 7/1/2026): records confirming the diagnosis are required, and approval runs 12 months. The 2026 criteria do not list a metformin step; the plan's own drug list may still add one.
Members who are approved typically pay $30-$100 a month, which is $360 to $1,200 over a year. A manufacturer savings card can lower that further when the plan covers the drug.
Appeal first: ask UHC for the written denial and the criteria it applied, and have your prescriber answer them in a letter of medical necessity. If the appeal fails, the cheapest cash route is compounded semaglutide or tirzepatide, from WellMedRx at $49/mo or Collective at $59/mo. Sellers that say they work with UHC include Evernow. A compounded drug is not FDA-approved as a finished product.

Glossary

The words sellers use, defined. Tap any term.

How coverage looks nationallyWork out the cash-pay difference
Sources & methodology — as of November 2026
  1. 1.KFF — Employer Health Benefits Annual Survey— Kaiser Family Foundation.
  2. 2.U.S. Department of Labor — ERISA and Employer Health Plans— U.S. Department of Labor, Employee Benefits Security Administration.
  3. 3.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.
  4. 4.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
  5. 5.GLP Watchdog insurer coverage index (manually curated formulary data)— GLP Watchdog.